Abstract: Objective：To investigate the effect of clinical and pathological factors on the clinical outcomes in those patients with the advanced cervical cancer who were experiencing the combined therapy with radiotherapy and chemotherapy. Methods：A total of 126 patients with the advanced cervical cancer who were receiving the radiotherapy combined with cisplatin were followed up for five years. Effect of those factors, such as FIGO stage, histological type, tumor grade and tumor size, on the survival rate was analyzed. Results：At of the end of the follow-up, 79 patients survived, and the five-year survival rate was 62.7%. 77 patients were in progression-free survival, the progression-free survival rate was 57.1%. The median follow-up was 45 months（Range＝8-69）. There were significant differences in the progression-free survival and the overall survival after the stratification analysis by age, level of tumor grade and FIGO classification. The Cox regression analysis showed that the tumor grade was significant related to the progression-free survival（P＜0.05）; and that the tumor grade and FIGO grade had a significant impact on overall survival（P＜0.05）. Adverse event included bone marrow suppression（21.4%）, gastrointestinal reaction（16.7%） and kidney dysfunction（6.3%）. Conclusions：Those patients with the advanced cervical cancer who have higher tumor grade and FIGO stage could have poor clinical outcomes of the combined therapy with radiotherapy and chemotherapy. The lower survival rate in those patients should be attended in clinical practice.

Key words: Uterine cervical neoplasms, Carcinoma, Radiotherapy, Drug therapy, combination, Regression analysis